Oncology Based In-Vivo CRO Market Size (2024 - 2029)

The oncology-based in-vivo CRO market is projected to experience significant growth during the forecast period, driven by increasing patient assistance programs, government initiatives for cancer awareness, and a rising global prevalence of cancer. Despite the challenges posed by the COVID-19 pandemic and issues related to the availability of alternatives and quality concerns, the market is expected to expand due to vital R&D initiatives and the growing demand for personalized medicine. The development of advanced cancer therapies, such as dendritic cell vaccines, further contributes to the market's expansion.

Market Size of Oncology Based In-Vivo CRO Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Oncology Based In-Vivo CRO Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 7.30 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Oncology Based In-Vivo CRO Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Oncology Based In-Vivo CRO Market Analysis

The Oncology Based In-Vivo CRO Market is anticipated to register a CAGR of 7.3% during the forecast period.

The COVID-19 pandemic has affected the healthcare systems globally and also has had a significant impact on the Oncology Based In-Vivo CRO Market. However, initiatives such as grant approval for vaccine production are expected to increase the market growth. For instance, in September 2022, the Gastro-Intestinal Research Foundation (GIRF) in Chicago granted Elicio Therapeutics a USD 2.8 million grant to fund research for two therapeutic cancer vaccines. ELI-007 is being developed to target BRAF gene mutations, whereas ELI-008 is being designed to target p53 hotspot mutations in solid tumors such as colorectal cancer, melanoma, and non-small cell lung cancer (NSCLC). Thus, the COVID-19 pandemic has impacted the oncology-based In-Vivo CRO market. However, the initiatives by key market players are expected to increase market growth during the forecast period.

The factors driving the market growth include increasing patient assistance programs (PAPs), increasing government initiatives for cancer awareness, the rising prevalence of cancer worldwide, vital R&D initiatives from key players, and the increasing demand for personalized medicine. According to the Globocan 2021 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths from cancer globally. According to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. The high disease burden fuels the demand for outsourcing R&D activities for effective drug development/treatment. Thus, the increasing incidence of cancer cases is expected to drive the need for advanced cancer therapies to treat patients effectively. The dendritic cell (DC) vaccine can be achieved by the in vitro culture of DC (patient's autologous dendritic cell) and tumor-associated antigen. The low toxicity of DC vaccines in clinical trials makes it possible to use optimistic predictions of their applicability in broader clinical practice, thereby increasing their adaptability. For instance, in December 2021, researchers at Moffitt Cancer Center are working to develop a dendritic cell vaccine targeting HER3, a protein involved in the growth and spread of many different cancer types, including bladder, breast, lung adenocarcinoma, prostate, and stomach.

Similarly, in November 2021, Bioanalytical Systems, Inc. launched its new contract research service brand, Inotiv. Inotiv started representing the union of the company's Seventh Wave Laboratories & Smithers Avanza Toxicology Services, working in vivo toxicology, pharmacology, bioanalysis, drug metabolism, and pharmacokinetic solutions. Thus, given the factors above, the oncology based in-vivo CRO market is expected to witness tremendous growth over the forecast period.

However, the availability of alternatives and quality issues with CRO hamper the market's growth.

Oncology Based In-Vivo CRO Industry Segmentation

As per the report's scope, the oncology-based In-Vivo CRO provides preclinical drug development, testing, and infection diagnosis research in oncology. The demand for research organizations in the In-Vivo contract has been growing as pharmaceutical companies have been increasing their pipeline of drugs to create and produce new molecules to retain substantial benefits and patent products in the marketplace. The Oncology Based In-Vivo CRO Market is segmented by Indication (Blood Cancer, Solid Tumors, and Other Indication), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX)), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Indication
Blood Cancer
Solid Tumors
Other Indications
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Oncology Based In-Vivo CRO Market Size Summary

The oncology-based In-Vivo CRO market is poised for significant growth, driven by a combination of increasing cancer prevalence, government initiatives, and advancements in personalized medicine. The market is experiencing a surge in demand for outsourcing research and development activities, fueled by the high global burden of cancer cases. This demand is further bolstered by the development of innovative therapies, such as dendritic cell vaccines, which offer low toxicity and promising clinical outcomes. The COVID-19 pandemic has posed challenges, but initiatives like grant approvals for cancer vaccine research are expected to propel market expansion. Key players in the industry are actively engaging in strategic collaborations and investments to enhance their market positions and drive technological advancements.

North America is anticipated to lead the oncology-based In-Vivo CRO market, supported by a high incidence of cancer and a robust framework for cancer therapy adoption. The region benefits from a concentration of major industry players, regulatory support, and substantial investments in research and development. The market's competitive landscape is characterized by the presence of prominent companies that are actively pursuing acquisitions and partnerships to strengthen their market share. Despite challenges such as the availability of alternatives and quality issues, the market is expected to witness substantial growth, driven by the increasing need for effective cancer treatments and the ongoing development of innovative therapeutic solutions.

Explore More

Oncology Based In-Vivo CRO Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising incidence of Cancer Globally

      2. 1.2.2 Increasing Initiatives by Market Players

    3. 1.3 Market Restraints

      1. 1.3.1 Availability of Alternatives and Quality issues with CRO

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Indication

      1. 2.1.1 Blood Cancer

      2. 2.1.2 Solid Tumors

      3. 2.1.3 Other Indications

    2. 2.2 By Model

      1. 2.2.1 Syngeneic

      2. 2.2.2 Xenograft

      3. 2.2.3 Patient Derived Xenograft (PDX)

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East & Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East & Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Oncology Based In-Vivo CRO Market Size FAQs

The Oncology Based In-Vivo CRO Market is projected to register a CAGR of 7.30% during the forecast period (2024-2029)

Crown Bioscience Inc., Charles River Laboratories, Inc., ICON plc, Taconic Biosciences, Inc. and Covance Inc. are the major companies operating in the Oncology Based In-Vivo CRO Market.

Oncology Based In-Vivo CRO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)